Delphi advisor to IRLAB Therapeutics AB (publ) in connection with IPO of SEK 115 million and listing on Nasdaq First North Premier

IRLAB is a drug discovery and development company providing novel treatment for disorders of the brain, with focus on Parkinsons disease and dementia. IRLAB has two drug candidates, IRL752 and IRL790, for which clinical phase 1 studies have been completed, three projects in pre-clinical phase as well as a research program that aims at identifying further drug candidates.

Delphi’s team consisted of inter alia Dag Fredlund (responsible partner), Annika Bergman, Hanne Kirnö and Kristina Lemke.